Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation
A Multi-Center, Open-Label, Two-Period Cross-Over, Patient-Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Iron Chelating Activity of DST-0509 (Deferasirox) Tablets in Thalassemia Patients With Inadequate Response to Standard Chelation Therapy
Sponsor: DisperSol Technologies, LLC
Listed as NCT03637556, this PHASE2 trial focuses on Thalassemia Major and remains completed. Sponsored by DisperSol Technologies, LLC, it has been updated 10 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Sep 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Oct 2020 [monthly]
Recruiting PHASE2
-
Sep 2019 — Dec 2019 [monthly]
Recruiting PHASE2
-
Sep 2018 — Sep 2019 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- DisperSol Technologies, LLC
For direct contact, visit the study record on ClinicalTrials.gov .